Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.69 |
| ▸ | ESRRA | P11474 | 7/20 | 0.69 |
| ▸ | MELK | Q14680 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | WEE1 | P30291 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916041 | 0.88 | ESR1 (0.86) | ESR1ESR2ESRRA | |
| SCHEMBL14915830 | 0.87 | ESRRA (0.65) | ESR1ESR2ESRRAMELK | |
| SCHEMBL15263766 | 0.84 | ESRRA (0.47) | ESR1ESR2ESRRAENPP2WEE1 | |
| SCHEMBL2591786 | 0.82 | ESR2 (1.00) | ESR1ESR2ESRRA | |
| SCHEMBL2589775 | 0.81 | ESRRA (1.00) | ESR1ESR2ESRRA | |
| SCHEMBL14915808 | 0.81 | ESR1 (0.74) | ESR1ESR2ESRRAWEE1 | |
| SCHEMBL14916386 | 0.80 | ESR1 (0.76) | ESR1ESR2ESRRA | |
| SCHEMBL14916720 | 0.80 | ESR1 (0.72) | ESR1ESR2ESRRA | |
| SCHEMBL14916028 | 0.79 | ESR1 (0.70) | ESR1ESR2ESRRAPTGS2PTGS1 | |
| SCHEMBL14916063 | 0.79 | ESRRA (0.73) | ESR1ESR2ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014039820-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | GTX, INC. (US) | 2014-03-13 | — | — | WO | claimed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | claimed |
| WO-2014039820-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | GTX, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014039820-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | GTX, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | AKR1C3, AKR1C1, AKR1C2 | ESR1 168/4885ESR2 511/4885ESRRA 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.